about
Radiation and concomitant chemotherapy for patients with glioblastoma multiformeA case of c-kit positive high-grade stromal endometrial sarcoma responding to Imatinib Mesylate.Extended-schedule dose-dense temozolomide in refractory gliomasPhase II trial of temozolomide for leptomeningeal metastases in patients with solid tumors.Randomized Phase II Study of Trabectedin and Doxorubicin Compared With Doxorubicin Alone as First-Line Treatment in Patients With Advanced Soft Tissue Sarcomas: A Spanish Group for Research on Sarcoma Study.Validation of the new Graded Prognostic Assessment scale for brain metastases: a multicenter prospective study.Geometrical Measures Obtained from Pretreatment Postcontrast T1 Weighted MRIs Predict Survival Benefits from Bevacizumab in Glioblastoma PatientsA Comparison of RNA-Seq Results from Paired Formalin-Fixed Paraffin-Embedded and Fresh-Frozen Glioblastoma Tissue Samples.Phase I/II trial of doxorubicin and fixed dose-rate infusion gemcitabine in advanced soft tissue sarcomas: a GEIS study.Translational research in glioblastoma multiforme: molecular criteria for patient selection.Efficacy of erlotinib in patients with relapsed gliobastoma multiforme who expressed EGFRVIII and PTEN determined by immunohistochemistry.Evolution of care for patients with relapsed glioblastoma.European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas.Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Onartuzumab Plus Bevacizumab Versus Placebo Plus Bevacizumab in Patients With Recurrent Glioblastoma: Efficacy, Safety, and Hepatocyte Growth Factor and O6-Methylguanine-DNAA phase II study of cisplatin, etoposide and gemcitabine in an unfavourable group of patients with carcinoma of unknown primary site.A phase II study of feasibility and toxicity of bevacizumab in combination with temozolomide in patients with recurrent glioblastoma.Clinical course of high-grade glioma patients with a "biopsy-only" surgical approach: a need for individualised treatment.Bevacizumab plus irinotecan in recurrent malignant glioma shows high overall survival in a multicenter retrospective pooled series of the Spanish Neuro-Oncology Research Group (GEINO).EANO guideline for the diagnosis and treatment of anaplastic gliomas and glioblastoma.Sequential dose-dense doxorubicin and ifosfamide for advanced soft tissue sarcomas: a Phase II trial by the Spanish Group for Research on Sarcomas (GEIS).CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas.Salvage surgical resection after high-dose ifosfamide (HDIF) based regimens in advanced soft tissue sarcoma (ASTS): a potential positive selection bias--a study of the Spanish group for research on sarcomas (GEIS).ATCT-05OBJECTIVE RESPONSE (OR) TO NEOADJUVANT TREATMENT IN GLIOBLASTOMA AND ITS IMPACT ON OVERALL SURVIVAL (OS). A META-ANALYSIS OF NEOADJUVANT TRIALS OF THE SPANISH GROUP FOR RESEARCH IN NEUROONCOLOGY (GEINO).SURG-01IS UNRESECTED GLIOBLASTOMA TRULY UNRESECTABLE? AN ANALYSIS OF BASAL MRI'S OF PATIENTS WITH UNRESECTED GLIOBLASTOMA INCLUDED IN THE GENOM009 TRIAL AND THE VARIABILITY OF SURGICAL APPROACHES.P17.04RANO CRITERIA APPLIED TO A PHASE II RANDOMIZED, MULTICENTER TRIAL COMPARING TEMOZOLOMIDE (TMZ) VS TMZ-PLUS-BEVACIZUMAB (BEV) BEFORE STANDARD TREATMENT IN UNRESECTABLE GLIOBLASTOMA (GBM) PATIENTS (P).GENOM 009 STUDY BY THE GEINO GROUP.Erratum to: Efficacy of erlotinib in patients with relapsed gliobastoma multiforme who expressed EGFRVIII and PTEN determined by immunohistochemistry.ET-12PHASE II STUDY OF ONARTUZUMAB PLUS BEVACIZUMAB VERSUS PLACEBO PLUS BEVACIZUMAB IN PATIENTS WITH RECURRENT GLIOBLASTOMA.Pseudoprogression as an adverse event of glioblastoma therapy.Epigenetic profiling to classify cancer of unknown primary: a multicentre, retrospective analysis.Efficacy and safety of Levetiracetam vs. other antiepileptic drugs in Hispanic patients with glioblastoma.IDH mutation status trumps the Pignatti risk score as a prognostic marker in low-grade gliomas.Results of a multicenter survey showing interindividual variability among neurosurgeons when deciding on the radicality of surgical resection in glioblastoma highlight the need for more objective guidelines.SEOM clinical guidelines for anaplastic gliomas (2017).Evidence-based management of adult patients with diffuse glioma - Authors' reply.Is a pretreatment radiological staging system feasible for suggesting the optimal extent of resection and predicting prognosis in glioblastoma? An observational study.SEOM guideline for the treatment of malignant glioma.Use of 201Tl SPECT imaging to assess the response to therapy in patients with high grade gliomas.Bevacizumab and temozolomide versus temozolomide alone as neoadjuvant treatment in unresected glioblastoma: the GENOM 009 randomized phase II trial.Tumour and serum MGMT promoter methylation and protein expression in glioblastoma patients.Phase II trial of irinotecan and metronomic temozolomide in patients with recurrent glioblastoma.
P50
Q26827957-B2A8E2D5-C64A-48E1-9E69-B4B3EC3905AAQ27824863-0D3145E8-2A3A-4AF6-AC7D-556A6CD57702Q33385736-96F32B8F-5569-40B7-9680-7DAEDEE5C57EQ33401308-E82C7DDD-FA88-420B-BAC6-C3F2B44A951CQ33432279-F6730462-6831-4CC2-8E03-F5C8E5C35AC4Q33834894-E086B767-58FE-45AB-8B8C-4D3B3C8D6B82Q36111620-2F0487EE-096A-46B5-A698-1C2F5A693439Q36259923-FDBDC498-F167-46D2-AA9A-D52E8B761490Q36614418-E63D4667-7CCF-441D-B711-D8B54BCC4FFDQ37137006-01D0AC0B-AE20-4FAA-A0DB-832A09EBC8FFQ37471694-ED2EC945-7DFC-4A88-B122-3B3DB3CA87E5Q37952240-314CA318-919F-4554-820C-C513D553BA55Q39291912-3A2FB3C0-3155-4899-A957-20D78386B1D7Q40441135-A6F0AC0B-9FBD-4677-9890-5620A36BB274Q40550991-79BACD6C-CC72-4B90-8069-2FECEA8246CFQ41701813-4BB1C25C-59A5-4CD5-A9BA-D6D859D88B07Q42523065-E275C815-F1B1-42CC-9000-F54490EA59F4Q43505131-A109A4D6-6197-4EBA-95F5-65C63115C2ACQ44200074-6C2E242F-AB19-46CE-9C4E-21FEAA269241Q44813453-D1ED4CDA-209C-4BED-ADCA-ADB77D1BC7CBQ45009128-FE417CB8-760A-486C-A280-431C809909C1Q45071656-3B1484D0-FFCE-4014-B0F1-F220A712C4D3Q45831059-E11A9F19-A7C2-4296-A4F0-48C903EEB4DCQ45835764-41023162-BC68-4766-8398-9617D9CD2BA1Q46661236-85CC8FC8-54D7-48D0-BD88-EC076C08DB70Q46716597-F3489B62-C020-4284-A0CE-81DCE160A2B0Q47100208-B1274423-11F3-4616-8934-54F665C79A38Q47164037-89CF80F6-F576-4088-A3A2-999EFD3FA9D9Q47700925-2823E695-4921-4C40-BC09-8ACD4B59B57AQ47949323-FEA31831-1718-480C-AD8D-6C9FC1B59B21Q48015833-C4B915DC-E68B-4D4E-8AE8-F7F157999880Q48124819-45753ABE-3EAB-4B4A-BFC9-3D593138F442Q48147847-05469A67-9B0B-42C6-B34F-9DF29F44CDCCQ48172740-A69FDD50-45BE-4650-8501-A98105C9FD70Q48334378-2B9B8D01-F60C-4F94-9360-17115EB16D00Q48464940-9DC80751-EC1A-4CFD-9CBB-A533157EEA46Q48488925-C314BC30-ECBB-41D3-A97E-E764893D42D7Q48925984-4637E298-1F5A-4A55-A10A-0BB86E0203BCQ48934243-A9ACC3F4-2AE7-4EEC-94F2-9BF5E8250DAAQ52146796-D6EA2E73-4186-4BC9-98FA-79DB12881973
P50
description
hulumtuese
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Carmen Balaña
@ast
Carmen Balaña
@en
Carmen Balaña
@es
Carmen Balaña
@fr
Carmen Balaña
@nl
Carmen Balaña
@sl
type
label
Carmen Balaña
@ast
Carmen Balaña
@en
Carmen Balaña
@es
Carmen Balaña
@fr
Carmen Balaña
@nl
Carmen Balaña
@sl
prefLabel
Carmen Balaña
@ast
Carmen Balaña
@en
Carmen Balaña
@es
Carmen Balaña
@fr
Carmen Balaña
@nl
Carmen Balaña
@sl
P106
P1153
56802274300
P21
P31
P496
0000-0003-0771-0390